PRINTER'S NO. 1306
No. 1025 Session of 2007
INTRODUCED BY ORIE, DINNIMAN, BOSCOLA, KITCHEN AND RAFFERTY, JULY 14, 2007
REFERRED TO FINANCE, JULY 14, 2007
AN ACT 1 Amending the act of June 26, 2001 (P.L.755, No.77), entitled "An 2 act establishing a special fund and account for money 3 received by the Commonwealth from the Master Settlement 4 Agreement with tobacco manufacturers; providing for home and 5 community-based care, for tobacco use prevention and 6 cessation efforts, for Commonwealth universal research 7 enhancement, for hospital uncompensated care, for health 8 investment insurance, for medical assistance for workers with 9 disabilities, for regional biotechnology research centers, 10 for the HealthLink Program, for community-based health care 11 assistance programs, for PACE reinstatement and PACENET 12 expansion, for medical education loan assistance and for 13 percentage allocation and appropriation of moneys," further 14 providing for establishment of special fund and account, for 15 health research program, for use of funds and for 16 accountability procedures; and assigning duties and 17 responsibilities to the Department of Health and the 18 Department of Community and Economic Development. 19 The General Assembly of the Commonwealth of Pennsylvania 20 hereby enacts as follows: 21 Section 1. Sections 303, 903, 906 and 910 of the act of June 22 26, 2001 (P.L.755, No.77), known as the Tobacco Settlement Act, 23 are amended to read: 24 Section 303. Establishment of special fund and account. 25 (a) Tobacco Settlement Fund.--There is hereby established a
1 special fund known as the Tobacco Settlement Fund. Except as 2 provided in subsection (b), all payments received by the 3 Commonwealth pursuant to the Master Settlement Agreement shall 4 be deposited by the Treasury Department in the fund. 5 (b) Health Account.--There is hereby established within the 6 fund the Health Endowment Account for Long-Term Hope. The 7 following amounts shall be deposited by the Treasury Department 8 into the account: 9 (1) The jurisdictional payment received by the 10 Commonwealth pursuant to the Master Settlement Agreement. 11 (2) The strategic contribution payments received by the 12 Commonwealth pursuant to the Master Settlement Agreement. 13 (3) Earnings derived from the investment of the money in 14 the fund after deduction of investment expenses, including 15 such earnings as may have accrued prior to the effective date 16 of this chapter. 17 (4) Earnings derived from the investment of the money in 18 the Health Account after deduction of investment expenses and 19 the approved expenses of the board. 20 [(5) Money received as a result of investments from the 21 Health Venture Investment Account.] 22 (c) Health Venture Investment Account.--There is hereby 23 established within the fund the Health Venture Investment 24 Account. Money received as a result of investments from the 25 Health Venture Investment Account shall be returned by the 26 Treasury Department to the Health Venture Investment Account to 27 support additional investments pursuant to the provisions of 28 section 305(f) and (g). 29 Section 903. Health research program. 30 (a) Program establishment.-- 20070S1025B1306 - 2 -
1 (1) There is established in the department a health 2 research program which shall be known as the Commonwealth 3 Universal Research Enhancement Program. Appropriations from 4 the fund to the department shall be used to fund research 5 projects and related infrastructure by eligible applicants. 6 This includes: 7 (i) biomedical research; 8 (ii) clinical research; and 9 (iii) health services research. 10 (2) Funds appropriated for the program may be used to 11 conduct peer reviews and performance reviews. 12 (b) Advisory committee.-- 13 (1) There is hereby established in the department the 14 Health Research Advisory Committee. 15 (2) The committee is comprised of the following: 16 (i) The secretary or a designee, who shall serve as 17 chairperson. 18 (ii) [Four] Nine members appointed by the 19 Governor[.], at least four of whom shall represent the 20 life sciences industry, with at least two of the four 21 being chosen from the small business community. 22 (iii) One member appointed by the President pro 23 tempore of the Senate and one member appointed by the 24 Minority Leader of the Senate. 25 (iv) One member appointed by the Speaker of the 26 House of Representatives and one member appointed by the 27 Minority Leader of the House of Representatives. 28 (v) The Secretary of Community and Economic 29 Development or a designee. 30 (3) Members appointed to the committee by the Governor 20070S1025B1306 - 3 -
1 must possess expertise in health care or research, with 2 representation by institution-based research specialists, 3 practicing clinicians, clinical investigators and public 4 health professionals. 5 (4) Terms are as follows: 6 (i) The secretary and the Secretary of Community and 7 Economic Development shall serve ex officio. 8 (ii) A member under paragraph (2)(ii) shall serve a 9 term of six years. 10 (iii) A member under paragraph (2)(iii) shall serve 11 a term of four years but may be removed at the pleasure 12 of the appointing authority. 13 (iv) A member under paragraph (2)(iv) shall serve a 14 term of two years but may be removed at the pleasure of 15 the appointing authority. 16 (v) An appointment to fill a vacancy shall be for 17 the period of the unexpired term or until a successor is 18 appointed and qualified. 19 (5) The committee shall meet as needed, but at least 20 twice a year, to fulfill the purposes provided for in this 21 chapter. A majority of the members of the committee 22 constitutes a quorum. A majority of the members of the 23 committee has authority to act upon any matter properly 24 before it. The committee is authorized to establish rules for 25 its operation and shall hold public hearings, as necessary, 26 to obtain public input and make recommendations to the 27 department regarding research priorities, evaluation and 28 accountability procedures and related issues. Meetings of the 29 committee shall be conducted under 65 Pa.C.S. Ch. 7 (relating 30 to open meetings). 20070S1025B1306 - 4 -
1 (6) Members shall receive no payment for their services. 2 Members who are not employees of State government shall be 3 reimbursed for necessary and reasonable expenses incurred in 4 the course of their official duties. 5 Section 906. Use of funds. 6 Research projects conducted under this section shall be 7 consistent with the priorities established under section 904(2). 8 Funds under this section shall be allocated for the following 9 purposes: 10 (1) Seventy percent of the funds appropriated under this 11 section shall be used to fund research pursuant to section 12 908. 13 (2) Fifteen percent of the funds appropriated under this 14 section shall be used to fund clinical and health services 15 research projects by eligible applicants. 16 (3) Fifteen percent of the funds appropriated under this 17 section shall be used to fund [other research projects by 18 eligible applicants.] life sciences research and development 19 activities conducted in Pennsylvania-based small businesses. 20 Section 910. Accountability procedures and department report. 21 (a) Requirements.--An applicant that receives a research 22 grant under this chapter shall be subject to a performance 23 review by the department upon completion of a research project 24 or more often as deemed necessary by the department. The 25 performance review shall be based on an evaluation process 26 developed by the department in consultation with the advisory 27 committee. Information shall be submitted by research grant 28 recipients and shall include, as applicable, the following: 29 (1) The progress made in achieving expected research 30 goals and objectives. 20070S1025B1306 - 5 -
1 (2) The extent of clinical activities initiated and 2 completed, detailing the number of treatment, prevention and 3 diagnostic studies; the number of hospitals and health care 4 professionals; the number of subjects relative to targeted 5 goals; and the extent of penetration of the studies 6 throughout the region or this Commonwealth. 7 (3) The number of peer-reviewed publications and the 8 number of licenses and patents filed, including commercial 9 development opportunities. 10 (4) Any changes in risk factors, services provided, 11 incidence of disease, death from disease, stage of disease at 12 the time of diagnosis or other relevant measures of the 13 outcome, impact and effectiveness of the research being 14 conducted. 15 (5) Any major discoveries, new drugs and new approaches 16 for prevention, diagnosis and treatment which are 17 attributable to the completed research project. 18 (6) Any other information deemed necessary by the 19 department. 20 (a.1) Department report.--The department shall submit to the 21 General Assembly an annual report describing specifically the 22 performance of research projects funded under this chapter 23 during the previous fiscal year. 24 (b) Penalty.--Notwithstanding any other provision of this 25 chapter, an applicant that receives an unfavorable review by the 26 department under subsection (a) may be subject to a reduction in 27 or ineligibility for research grant funding under this chapter. 28 Section 2. This act shall take effect in 60 days. F20L35JS/20070S1025B1306 - 6 -